ArticleCommunications biology2026
Integrative structural insights into the IgG-FcRn interactions revealed by engineered FcRn-immobilized affinity chromatography.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Molecular interactions between therapeutic antibodies and neonatal Fc receptor (FcRn) are major contributors to the long serum half-life of antibodies. Therefore, the in vitro affinity of IgG for FcRn is an important indicator of in vivo pharmacokinetic properties. However, the molecular basis of IgG-FcRn interactions is not fully understood from experimental and structural perspectives. Affinity evaluation using surface plasmon resonance is difficult. The molecular mechanism by which domains other than Fc or surface charges affect FcRn binding remains unclear. In this study, we developed an engineered FcRn-immobilized column for affinity chromatography. We analyzed various types of antibodies to link physicochemical characteristics and FcRn affinity. Furthermore, analysis using charge-engineered mutants indicated that the lateral surface of L chain also affects the FcRn affinity. Finally, we presented a structural model of the IgG-FcRn complex to discuss the molecular mechanism of how the charges at L chain affect the FcRn affinity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.